Additionally, when patients were administered a bacterial mixture including two probiotics, Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1), these microorganisms were found to adhere to the colonic mucosa, reduce the concentration of intestinal pathogens, and regulate the local formation of an anti-cancer immune environment, as shown by significantly reduced proliferation of CD83-123, CD83-11c, and CD83-HLA-DR subsets in subjects receiving probiotics compared to controls [98]. The gene discussed is CD83; the disease is cancer.